Loading...
CERT logo

Certara Community

NasdaqGS:CERT Community
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 15 Fair Values set on narratives written by author

Community Investing Ideas

CERT logo
Certara

Analysts Maintain Certara Price Target as Pharma Sector Recovery and New Developments Drive Outlook

Key Takeaways Regulatory approvals and industry trends are boosting demand for Certara's biosimulation platforms, expanding its market and supporting stronger revenue streams. Product innovation, strategic acquisitions, and cloud-based SaaS models increase customer retention, cross-selling, and margins, enhancing long-term profitability and earnings stability.Read more

View narrative
0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
US$14.75
43.9% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
8.4% p.a.
Profit Margin
9.28%
Future PE
62.36x
Share price in 2028
US$18.75